<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154244</url>
  </required_header>
  <id_info>
    <org_study_id>113417</org_study_id>
    <nct_id>NCT01154244</nct_id>
  </id_info>
  <brief_title>Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea</brief_title>
  <acronym>SURPRISE</acronym>
  <official_title>Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is investigating the clinical characteristics of newly diagnosed,
      drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:To investigate whether insulin resistance or insulin deficiency is primary
      in the pathogenesis of type 2 diabetes mellitus in Korea Secondary Objectives:To investigate
      proportion of patients with severe insulin deficiency at diagnosis,To investigate proportion
      of metabolic syndrome in patients with newly diagnosed, drug-naïve type 2 diabetes
      mellitus,To investigate proportion of obesity in patients with newly diagnosed, drug-naïve
      type 2 diabetes mellitus
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance assessed using HOMA-IR</measure>
    <time_frame>within 3months after DM diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with severe insulin deficiency assessed using C-peptide</measure>
    <time_frame>within 3months after DM diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of metabolic syndrome in patients</measure>
    <time_frame>within 3months after DM diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of obesity in patients</measure>
    <time_frame>within 3months after DM diagnosis</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1439</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Drug naive type II DM</arm_group_label>
    <description>Newly diagnosed type II Diabetes Mellitus</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HOMA-IR</intervention_name>
    <description>Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile</description>
    <arm_group_label>Drug naive type II DM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Newly diagnosed Type II DM, Drug naive
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:Newly diagnosed, drug naïve type 2 DM patients who gave informed
        consent, Diagnosis of type 2 DM will be made according to ADA guideline 2009 Exclusion
        Criteria:Patients age under 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-749</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>June 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2010</study_first_posted>
  <last_update_submitted>January 22, 2011</last_update_submitted>
  <last_update_submitted_qc>January 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>E.D. Derilus; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Insulin deficiency</keyword>
  <keyword>HOMA-IR</keyword>
  <keyword>Drug naive</keyword>
  <keyword>Diabetes mellitus, type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

